TakedaPrefer Sterling in Google
Add sterlingcharts.com as a preferred source so our charts can appear with a preferred badge in Google Top Stories, AI Mode, and AI Overviews.
Register for a premium account to gain access to Sterling AI.
Get StartedThings you can ask Sterling:
| Period | Bucket | Q1 FY2025 | Q1 FY2026 | CER % |
|---|---|---|---|---|
| ENTYVIO | Core In-line | 232.5 | 268.3 | 3.8 |
| GATTEX/REVESTIVE | Core In-line | 34.8 | 41.4 | 8.4 |
| TAKECAB/VOCINTI | Core In-line | 35 | 37.4 | 2.9 |
| TAKHZYRO | Core In-line | 55.1 | 59.9 | -2.2 |
| Immunoglobulin | Core In-line | 194 | 213.9 | -0.6 |
| Albumin | Core In-line | 32.2 | 34.6 | -5 |
| ADCETRIS | Core In-line | 37.2 | 48.5 | 14.4 |
| EOHILIA | New Launch | 2 | 2.3 | 2.5 |
| LIVTENCITY | New Launch | 10.5 | 14.1 | 20.8 |
| ADZYNMA | New Launch | 2.4 | 4.1 | 52.2 |
| FRUZAQLA | New Launch | 12.3 | 17.1 | 26.8 |
| QDENGA | New Launch | 8.8 | 11.5 | 15.2 |
| VYVANSE/ELVANSE | LOE (U.S. Aug 2023) | 57.9 | 54.1 | -17 |
Chobei Takeda I starts a medicine business in Osaka. The listed company is among the oldest on this roster. Vaccines are a Japan/dengue lens, not the whole P&L.
EMA approves Qdenga (dengue) in December 2022. The vaccine lens is Japan and dengue endemic markets, not a global P&L.